A recent breakthrough in the treatment of phenylketonuria (PKU) is set to stimulate demand for more regular screening of blood phenylalanine (Phe) levels in PKU patients. The introduction of the first FDA-approved prescription medication that reduces blood Phe levels in patients will result in more regular screening of PKU patients to monitor their Phe levels.
The Biochrom 30 Physiological is a compact bench-top instrument designed for metabolic disorder screening and research applications.
The instrument’s lithium high-performance columns perform a full routine analysis of physiological fluids, enabling the determination of up to 53 different amino acids, including physiologically important amino acids, for early detection of hereditary metabolic disorders and the effectiveness of nutrient absorption.
The Biochrom 30 Physiological incorporates customised ‘load and go’ applications for simplicity of operation, and the instrument’s software supports a graphical user interface that fully integrates instrument control and data handling functions and provides flexible data export and customised reporting.
www.biochrom.co.uk
